Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

October 31, 2016

Conditions
Delayed Function of Renal Transplant
Interventions
DRUG

SANGUINATE

Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1

DRUG

Normal Saline

Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.

Trial Locations (20)

15213

University of Pittsburg Medical Center, Pittsburgh

17104

Central Pennsylvania Transplant Foundation, Harrisburg

20007

Medstar Georgetown University Hosiptal, Washington D.C.

29425

Medical University of South Carolina, Charleston

30912

Augusta University, Augusta

33606

Tampa General Hospital, Tampa

43537

University of Toledo, Toledo

44195

The Cleveland Clinic, Cleveland

48212

Henry Ford Hospital, Detroit

53706

University of Wisconsin, Madison

60611

Northwestern University, Chicago

60612

UIC University of Illinois at Chicago, Chicago

70121

Ochsner Medical Center, New Orleans

77030

Houston Methodist Hospital, Houston

85054

Mayo Clinic Phoenix, Phoenix

90024

University of California, Los Angeles, Los Angeles

92123

California Institute of Renal Research, San Diego

94115

California Pacific Medical Center, San Francisco

94143

University of California San Francisco, San Francisco

07039

Saint Barnabas Medical Center, Livingston

Sponsors
All Listed Sponsors
lead

Prolong Pharmaceuticals

INDUSTRY